Asset Acquisition, Percentage of Ownership Acquired

No definition available.

Name:	bmy_AssetAcquisitionPercentageOfOwnershipAcquired
Namespace Prefix:	bmy_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Asset Acquisition, Share Price

+ References

No definition available.

+ Details

Name:	bmy_AssetAcquisitionSharePrice
Namespace Prefix:	bmy_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Business Combination, Number Of Rights Received Per Share

+ References

No definition available.

+ Details

Name:	bmy_BusinessCombinationContingentValueNumberOfRightsReceived
Namespace Prefix:	bmy_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Business Combination, Contingent Value Payout, Period

+ References

No definition available.

+ Details

Name:	bmy_BusinessCombinationContingentValuePayoutPeriod
Namespace Prefix:	bmy_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	instant

- Definition

Business Combination, Contingent Value, Share Price

+ References

No definition available.

+ Details

Name:	bmy_BusinessCombinationContingentValueSharePrice
Namespace Prefix:	bmy_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Collaborative Arrangement Contingent Payments Maximum Exposure

+ References

No definition available.

+ Details

Name:	bmy_CollaborativeArrangementContingentPaymentsMaximumExposure
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

License and Other Arrangements Upfront Payments

+ References

No definition available.

+ Details

Name:	bmy_LicenseAndOtherArrangementsUpfrontPayments
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Licensing Arrangements

+ References

No definition available.

+ Details

Name:	bmy_LicensingArrangementsLineItems
Namespace Prefix:	bmy_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Payment And Royalty Allocation

+ References

No definition available.

+ Details

Name:	bmy_PaymentAndRoyaltyAllocation
Namespace Prefix:	bmy_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Payments For Asset Acquisitions

+ References

No definition available.

+ Details

Name:	bmy_PaymentsForAssetAcquisitions
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Payments for Asset Acquisitions, Net Of Cash Acquired

+ References

No definition available.

+ Details

Name:	bmy_PaymentsForAssetAcquisitionsNetOfCashAcquired
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percentage Of Net Sales Payable To Alliance Partner

+ References

No definition available.

+ Details

Name:	bmy_PercentageOfNetSalesPayableToAlliancePartner
Namespace Prefix:	bmy_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Settlement, Contingent Development, Change In Control Proceeds

+ References

No definition available.

+ Details

Name:	bmy_SettlementContingentDevelopmentChangeInControlProceeds
Namespace Prefix:	bmy_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessAcquisitionSharePrice
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 30
-Paragraph 8
-SubTopic 30
-Topic 805
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479637/805-30-30-8

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-SubTopic 30
-Topic 805
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479581/805-30-50-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 30
-Paragraph 7
-SubTopic 30
-Topic 805
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479637/805-30-30-7

+ Details

Name:	us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of liability recognized arising from contingent consideration in a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479581/805-30-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479668/805-30-25-6

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 35
-Paragraph 1
-Subparagraph (b)
-SubTopic 30
-Topic 805
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479613/805-30-35-1

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479907/805-20-50-1

+ Details

Name:	us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of intangible assets, excluding goodwill, acquired at the acquisition date.

+ References

+ Details

Name:	us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of inventory recognized as of the acquisition date.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 55
-Paragraph 37
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479303/805-10-55-37

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479907/805-20-50-1

+ Details

Name:	us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of income related to nonoperating activities, classified as other.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(7)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_OtherNonoperatingIncome
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479581/805-30-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-13

+ Details

Name:	us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=bmy_NimbusTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	bmy_LicensingAndOtherArrangementsAxis=bmy_KeytrudaRoyaltiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=bmy_BristolMyersSquibbMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=bmy_OnoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	bmy_LicensingAndOtherArrangementsAxis=bmy_NimbusTherapueticsTYK2InhibitorMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=bmy_RayzeBioMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AwardTypeAxis=bmy_UnvestedEquityAwardsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=bmy_MiratiTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bmy_AcquiredMarketedProductRightsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=bmy_InventoryPurchasePriceFairValueAdjustmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=bmy_KarunaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AwardTypeAxis=bmy_VestedEquityAwardsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=bmy_AcquiredIPRDMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS - Narrative (Details) $ / shares in Units, $ in Millions				1 Months Ended	3 Months Ended		12 Months Ended	36 Months Ended
	Mar. 18, 2024 USD ($) $ / shares	Feb. 26, 2024 USD ($) $ / shares	Jan. 23, 2024 USD ($) right $ / shares	Feb. 28, 2023 USD ($)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2023	Dec. 31, 2026
Licensing Arrangements [Line Items]
Business combination, contingent value, number of rights received \| right			1
Nimbus Therapeutics
Licensing Arrangements [Line Items]
Upfront payments				$ 4,000
Keytruda royalties
Licensing Arrangements [Line Items]
Percentage of net sales payable to alliance partner							6.50%
Keytruda royalties \| Forecast
Licensing Arrangements [Line Items]
Percentage of net sales payable to alliance partner								2.50%
Keytruda royalties \| Forecast \| Bristol-Myers Squibb
Licensing Arrangements [Line Items]
Payment and royalty allocation								75.00%
Keytruda royalties \| Forecast \| Ono
Licensing Arrangements [Line Items]
Payment and royalty allocation								25.00%
Nimbus Therapuetics TYK2 Inhibitor
Licensing Arrangements [Line Items]
Contingent sales-based milestones				$ 2,000
Other						$ 400
Nimbus Therapuetics TYK2 Inhibitor \| Nimbus Therapeutics
Licensing Arrangements [Line Items]
Change in control proceeds				10.00%
Percentage of ownership acquired				100.00%
RayzeBio
Licensing Arrangements [Line Items]
Share price (in usd per share) \| $ / shares		$ 62.50
Total consideration		$ 4,147
Business combination, consideration transferred		3,600
Intangible assets		3,700
RayzeBio \| IPRD
Licensing Arrangements [Line Items]
Business combination, recognized identifiable assets acquired and liabilities assumed, indefinite-lived intangible assets		1,700
RayzeBio \| R&D technology
Licensing Arrangements [Line Items]
Business combination, recognized identifiable assets acquired and liabilities assumed, indefinite-lived intangible assets		2,000
RayzeBio \| Unvested Equity Awards
Licensing Arrangements [Line Items]
Total consideration		274
Mirati Therapeutics
Licensing Arrangements [Line Items]
Share price (in usd per share) \| $ / shares			$ 58.00
Total consideration			$ 4,801
Business combination, consideration transferred		3,500	$ 4,100
Business combination, contingent value, share price (in dollars per share) \| $ / shares			$ 12.00
Continent consideration liability			$ 1,000
Business combination, contingent value payout, period			7 years
Intangible assets			$ 4,225
Inventories			215
Mirati Therapeutics \| Acquired marketed product rights
Licensing Arrangements [Line Items]
Intangible assets		$ 640
Mirati Therapeutics \| Unvested Equity Awards
Licensing Arrangements [Line Items]
Total consideration			$ 114
Inventory Purchase Price Fair Value Adjustment
Licensing Arrangements [Line Items]
Inventories					$ 148
Karuna
Licensing Arrangements [Line Items]
Asset acquisition, share price (in dollars per share) \| $ / shares	$ 330.00
Payments for asset acquisitions	$ 14,027
Payments for asset acquisitions, net of cash acquired	12,900
Karuna \| Vested Equity Awards
Licensing Arrangements [Line Items]
Payments for asset acquisitions	1,100
Karuna \| Unvested Equity Awards
Licensing Arrangements [Line Items]
Payments for asset acquisitions	$ 289
Karuna \| Acquired IPRD
Licensing Arrangements [Line Items]
Payments for asset acquisitions					$ 12,100